Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ALINA
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
- NCT03456076 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Deep
We haven't built an HCP commentary report on ALINA (alectnib, vinorelbine and 4 more in Carcinoma, Non-Small-Cell Lung) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ALINA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 198 | |
| YouTube | 99 | |
| Podcasts | 63 | |
| X videos | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Alectnib; Cisplatin; Vinorelbine; Gemcitabine; Pemetrexed; Carboplatin
- Arms
- Alectinib · Experimental
- Platinum-Based Chemotherapy · Active comparator
- Enrollment
- 257
- Primary outcomes
- Disease-free Survival (DFS), as Assessed by the Investigator
- Sponsor
- Hoffmann-La Roche
- Start
- Aug 16, 2018
- Primary completion
- Jun 26, 2023
- Results posted
- Yes
- Registry record
- NCT03456076 · updated Oct 14, 2026
Publications
linked from the registry- Dziadziuszko R, Ahn JS, Barlesi F, Solomon BJ, Wu YL, Bondarenko I, Hochmair M, Horinouchi H, Lee DH, Lee JS, Planchard D, Rittmeyer A, Zhong W, Adler L, Archer V, Cardona A, Petric P, Scalori A, Ding B, Mamolo C, Smoljanovic V, Nishio M. Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2026 Sep;27(9):1110-1119. doi: 10.1016/S1470-2045(26)00283-4. PubMed 42636834
- Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL. Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial. Lung Cancer. 2026 Jun;216:109385. doi: 10.1016/j.lungcan.2026.109385. Epub 2026 Mar 28. PubMed 41996761
- Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Lohmann TO, Xu T, Cardona A, Hiles L, Noe J, Solomon BJ. Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer. Future Sci OA. 2025 Dec;11(1):2578145. doi: 10.1080/20565623.2025.2578145. Epub 2025 Nov 11. PubMed 41217067
- Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. PubMed 38598794